Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 60.4% | +64.8% |
| KATAKAM, SUDHAKAR | 1 | 74.7% | +23.6% |
| SAOUD, CHRISTINE J | 1 | 58.0% | +37.6% |
| BERHANE, SELAM | 1 | 59.0% | +55.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681904 | ANTI-VEGF A AND VEGF C BISPECIFIC ANTIBODIES AND USE THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| 18288872 | OXM3 STORAGE AGENT, OXM3 FORMULATION AND PREPARATION METHOD | KATAKAM, SUDHAKAR | — |
| 17788181 | USE OF FUSION PROTEIN IN TREATMENT OF AGE-RELATED MACULAR DEGENERATION | SAOUD, CHRISTINE J | — |
| 17642978 | USE OF ANTI-PCSK9 ANTIBODY IN METHOD FOR PREVENTING OR TREATING CHOLESTEROL-RELATED DISEASE | BERHANE, SELAM | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1645 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18681904 | ANTI-VEGF A AND VEGF C BISPECIFIC ANTIBODIES AND USE THEREOF | CUNNINGCHEN, KATHLEEN MARY | — | DP | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18288872 | OXM3 STORAGE AGENT, OXM3 FORMULATION AND PREPARATION METHOD | KATAKAM, SUDHAKAR | 1658 | §103 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 17788181 | USE OF FUSION PROTEIN IN TREATMENT OF AGE-RELATED MACULAR DEGENERATION | SAOUD, CHRISTINE J | 1645 | §112DP | Non-Final OA | — | Pending | Jun 22, 2022 |
| 17642978 | USE OF ANTI-PCSK9 ANTIBODY IN METHOD FOR PREVENTING OR TREATING CHOLESTEROL-RELATED DISEASE | BERHANE, SELAM | 1675 | §103§112DP | Final Rejection | — | Pending | Mar 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial